Vai al contenuto principale
xMedica

NCT06535854ClinicalTrials.gov

Prevail Global Study

A Randomized Controlled Study of the Prevail Drug-Coated Balloon in Subjects With In-stent Restenosis and a Single Arm Prospectively Enrolled Study of the Prevail Drug-Coated Balloon for de Novo Lesions in Small Vessel Disease (Prevail Global).

In reclutamentoAccetta partecipanti ora, secondo la scheda del registro.
Contatta questo studio

In breve

The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.

Interventistico1205 partecipanti ricercati79 centri9 paesi

Categorie

Registrato in 1 registro

Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.

Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.

Ti interessa questo studio?

Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-08-02; recorded start 2025-02-24
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 10 other studies in this databaseCounted from the lead sponsor named in the record (Medtronic Vascular)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding7/20

    Single-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 51 sites

  • Data monitoring committee7/7

    A data monitoring committee is in place

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study, international in scope: 1,205 participants (target), run at 79 sites, across 9 countries.

How this score is built
  • Enrolment31/40

    1,205 participants (target)

  • Site count20/25

    51 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 72 months

  • Sponsor scale3/10

    Medtronic Vascular has led 11 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Sintesi

The purpose of the study is to evaluate the clinical safety and efficacy of the Prevail DCB.

The Prevail Global study is a prospective, premarket, interventional, multi-center, global, dual cohort clinical study enrolling subjects undergoing percutaneous coronary intervention for in-stent restenosis (ISR Cohort) in a randomized controlled study of the Prevail Drug-Coated Balloon, and subjects undergoing percutaneous coronary intervention of the Prevail Drug-Coated Balloon for de novo lesions in small vessel disease (DNSV Cohort) in a single arm prospectively enrolled study. In the ISR Cohort this will be accomplished by randomizing subjects to either a Prevail DCB arm or an Agent DCB arm to compare results of the treatment of ISR with coronary lesions previously treated with DES or BMS in native coronary arteries. In the DNSV Cohort this will be accomplished through collection of data to compare results of the Prevail DCB to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease. Subjects will be enrolled at approximately 85 study sites; the same study sites will be used for enrollment of both cohorts. The enrollment period is anticipated to be approximately 12 months. Subjects will remain in the study with follow-up clinical assessments through 5 years, study exit, or death, whichever comes first.

Patologie

  • Coronary Artery Disease

Idoneità

Idoneità
SessoTutti
Età18 Years – Nessun massimo
Volontari saniNo

Idoneità come riportata nel registro

Inclusion Criteria: * ≥ 18 years * Negative pregnancy test * Stable or unstable angina, positive functional test, or stable NSTEMI * Life expectancy \>1 year * Willing and able to cooperate with study procedures and required follow up evaluations Exclusion Criteria: * Known hypersensitivity or contraindication to antiplatelet medications or a sensitivity to contrast media which cannot be adequately pre-medicated * History of an allergic reaction or significant sensitivity to paclitaxel or any other analogue or derivative * Platelet count \< 100,000 cells/mm³ or \> 700,000 cells/mm³, or a white blood cell (WBC) count \< 3,000 cells/mm³ * Renal insufficiency (or failure) * Acute MI * Previous PCI of the target vessel within 6 months prior to the procedure * Planned PCI of any vessel within 72 hours post-index procedure and/or planned PCI of the target vessel within 12 months post-procedure * History of a stroke or transient ischemic attack (TIA) * Active peptic ulcer or upper gastrointestinal (GI) bleeding * History of bleeding diathesis or coagulopathy or will refuse blood transfusions * Documented left ventricular ejection fraction (LVEF) \<30% * Planned surgery that would cause interruption in recommended DAPT duration per current guidelines * Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS or other coronary artery imaging procedures

Idoneità in frasi semplici

I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.

Disegno dello studio

Disegno dello studio
Tipo di studioInterventistico
FaseNon applicabile
AssegnazioneRandomizzata
Modello di interventoPARALLEL
Finalità principaleTREATMENT
MascheramentoSINGLE (1)
Arruolamento1205 partecipanti ricercati

Sponsor e collaboratori

  • Medtronic Vascular Sponsor

Bracci e interventi

  • ISR Cohort Prevail DCBEXPERIMENTAL

    To evaluate the clinical safety and efficacy of the Prevail DCB in the treatment of ISR with coronary lesions previously treated with drug-eluting or bare metal stents in native coronary arteries.

  • DNSV Cohort (RVD 2.0 - 2.75mm)EXPERIMENTAL

    To evaluate the clinical safety and efficacy of the Prevail DCB as compared to a DES historical control in subjects undergoing PCI for de novo lesions in small vessel disease.

Interventi

  • Dispositivo Agent DCB

    The Agent Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR).

  • Dispositivo Prevail DCB

    The Prevail Paclitaxel-coated PTCA Balloon Catheter is intended for percutaneous transluminal coronary angioplasty (PTCA) in the coronary arteries with a vessel diameter from 2.00 mm to 4.00 mm to treat in-stent restenosis (ISR) and to treat de novo lesions in small vessel disease.

Esiti misurati

  1. Esito primario

    ISR Cohort Primary Analysis

    The TLF rate of the Prevail DCB arm at 12 months post procedure compared to the Agent DCB arm for non-inferiority

    Orizzonte temporale 1 year post-procedure

  2. Esito primario

    DNSV Cohort Primary Analysis

    The TLF rate of the Prevail DCB arm at 12 months post procedure compared to a DES historical control

    Orizzonte temporale 1 year post-procedure

  3. Esito secondario

    Acute success

    Acute success (device, lesion, and procedure) through hospital discharge only

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  4. Esito secondario

    All deaths

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  5. Esito secondario

    Cardiac death

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  6. Esito secondario

    All myocardial infarction (MI), including target vessel myocardial infarction (TVMI)

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  7. Esito secondario

    Clinically-driven target lesion revascularization (cd-TLR) defined as repeat PCI or CABG to the target lesion

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  8. Esito secondario

    Clinically-driven target vessel revascularization (cd-TVR)

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  9. Esito secondario

    Major adverse cardiac event (MACE) defined as composite of death, MI, or repeat cd-TLR

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  10. Esito secondario

    Target lesion failure (TLF) defined as composite of cardiac death, TVMI, or cd-TLR

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  11. Esito secondario

    Target vessel failure (TVF) defined as composite of cardiac death, TVMI, or cd-TVR

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

  12. Esito secondario

    Target lesion thrombosis (TLT) (definite or probable) according to Academic Research Consortium (ARC) definition

    Orizzonte temporale hospital discharge, 30 days, and 6, 12, 24, 36, 48, and 60 months

Date

Date
Data di inizio24 febbraio 2025 (effettiva)
Conclusione primaria1 febbraio 2027 (stimata)
Conclusione1 febbraio 2031 (stimata)
Prima pubblicazione2 agosto 2024 (effettiva)
Ultimo aggiornamento21 ottobre 2026
Risultati pubblicatiNon indicato nella scheda del registro
Stato verificato l'ultima voltaottobre 2026

«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.

Centri

78 centri stanno reclutando

Canada

Canada
StrutturaCittàStato o regioneStato
Montreal Heart InstituteMontrealIn reclutamento
Hôpital du Sacre Coeur de MontrealMontrealIn reclutamento
University of Ottawa Heart InstituteOttawaIn reclutamento
Toronto General HospitalTorontoIn reclutamento
Vancouver General HospitalVancouverIn reclutamento

Germany

Germany
StrutturaCittàStato o regioneStato
Herzzentrum Dresden GmbH UniversitätsklinikDresdenIn reclutamento
Universitat des SaarlandesHomburgIn reclutamento
MediClin Herzzentrum Lahr / BadenLahrIn reclutamento

Hong Kong

Hong Kong
StrutturaCittàStato o regioneStato
Queen Mary HospitalHong KongIn reclutamento

Ireland

Ireland
StrutturaCittàStato o regioneStato
Mater Private NetworkDublinIn reclutamento
Galway University Hospitals - University Hospital Galway (UHG)GalwayIn reclutamento

Japan

Japan
StrutturaCittàStato o regioneStato
Teikyo University HospitalItabashi-kuTokyoIn reclutamento
Shonan Kamakura General HospitalKamakuraKanagawaIn reclutamento
Kokura Memorial HospitalKitakyushuFukuokaIn reclutamento
Sendai Kousei HospitalSendaiMiyagiIn reclutamento
Saiseikai Yokohamashi Tobu HospitalYokohamaKanagawaIn reclutamento

Singapore

Singapore
StrutturaCittàStato o regioneStato
Sengkang General HospitalSingaporeIn reclutamento
Tan Tock Seng HospitalSingaporeIn reclutamento

South Korea

South Korea
StrutturaCittàStato o regioneStato
Keimyung University Dongsan HospitalDaeguIn reclutamento
Korea University Anam HospitalSeoulIn reclutamento
Seoul Saint Marys HospitalSeoulIn reclutamento
Seoul National University HospitalSeoulIn reclutamento
Asan Medical CenterSeoulIn reclutamento

United Kingdom

United Kingdom
StrutturaCittàStato o regioneStato
The Newcastle upon Tyne Hospitals NHS Foundation Trust - Freeman HospitalNewcastle upon TyneIn reclutamento

United States

United States
StrutturaCittàStato o regioneStato
Lehigh Valley Hospital - Cedar CrestAllentownPennsylvaniaIn reclutamento
AnMed Health Medical CenterAndersonSouth CarolinaIn reclutamento
University of Michigan Health System - University HospitalAnn ArborMichiganIn reclutamento
Emory University Hospital MidtownAtlantaGeorgiaIn reclutamento
Piedmont Atlanta HospitalAtlantaGeorgiaIn reclutamento
The University of Alabama at BirminghamBirminghamAlabamaIn reclutamento
Cardiology P.C.BirminghamAlabamaIn reclutamento
Kaleida HealthBuffaloNew YorkIn reclutamento
Virtua Our Lady of Lourdes HospitalCamdenNew JerseyIn reclutamento
Medical University of South Carolina (MUSC)CharlestonSouth CarolinaIn reclutamento
Advocate Illinois Masonic Medical CenterChicagoIllinoisIn reclutamento
The Lindner Research CenterCincinnatiOhioIn reclutamento
BayCare Health SystemClearwaterFloridaIn reclutamento
University Hospitals Cleveland Medical CenterClevelandOhioIn reclutamento
OhioHealth Riverside Methodist HospitalColumbusOhioIn reclutamento
Baylor Heart & Vascular HospitalDallasTexasIn reclutamento
Saint Elizabeth HealthcareEdgewoodKentuckyIn reclutamento
M Health Fairview ClinicEdinaMinnesotaRitirato
Parkview HealthFort WayneIndianaIn reclutamento
North Florida Regional Medical CenterGainesvilleFloridaIn reclutamento
Corewell HealthGrand RapidsMichiganIn reclutamento
The Moses H Cone Memorial HospitalGreensboroNorth CarolinaIn reclutamento
UPMC Pinnacle Harrisburg CampusHarrisburgPennsylvaniaIn reclutamento
HCA Houston Medical CenterHoustonTexasIn reclutamento
Huntsville HospitalHuntsvilleAlabamaIn reclutamento
Saint Lukes Mid America Heart InstituteKansas CityMissouriIn reclutamento

Nella scheda del registro sono indicati altri 29 centri.

Documenti dello studio

In questa scheda del registro non sono collegati documenti.

Modifiche nel tempo

  1. 21 ottobre 2026

    Centro aggiunto

    28 sites added (79 total)

    5179